Cholesterol fractions and apolipoproteins during endometriosis treatment by a gonadotrophin releasing hormone (GnRH) agonist implant or by danazol

What Was Tested

The paper reports a study of Buserelin in the context of endometriosis, published as a randomized controlled trial.

The evaluation of cholesterol fractions and apoproteins during ovarian suppression by a GnRH agonist implant vs danazol in the treatment of endometriosis.

Who Took Part

The study group was 33 patients.

The age groups tagged for this paper are adults, women only.

Triglycerides, cholesterol (C), LDL-C, HDL-C subfractions and apoproteins A-1 and B were measured at admission, at months 2, 4 and 6 of treatment and at month 2 post-treatment.

How the Study Was Run

In design terms this was a randomized study.

The patients were allocated by chance, so the Buserelin group and the comparison group should start out alike.

What Was Measured

Topics PubMed links to this paper include Apolipoproteins, Buserelin, Cholesterol, HDL, Cholesterol, LDL, Danazol, Endometriosis and Estradiol.

What This Means in Plain Language

The paper is a randomized study of Buserelin in 33 patients in people with endometriosis.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1991 (Clinical endocrinology), a journal based in England.

More context: the Buserelin compound page, Endometriosis research.